digital PCR
COVID-19 accelerated the growth of several product portfolios, but under CEO Thierry Bernard, the company is ready to put the pandemic behind it — mostly.
The company has launched its lower-throughput Cobas 5800 instrument in Europe and plans to launch the Digital LightCycler in Q3.
Qiagen, Exosome Dx Building Urine-Based Digital PCR Workflow for FGFR Mutations in Bladder Cancer
Premium
The firms will present a clinical comparison study using the workflow to detect FGFR mutations in 50 urothelial cancer patients later this year.
The company plans to publish new data on clinical sensitivity and specificity and has initiated multiple studies investigating new use cases.
Stilla Technologies Partners With ID-Solutions for Oncology MDx
The partners will commercialize a line of oncology mutation panels on the Stilla Naica digital PCR system.
Aug 1, 2019
Bio-Rad Q2 Revenues Down 1 Percent
Feb 28, 2019
Bio-Rad Q4 Revenues Down 1 Percent, Beat Estimates
Feb 22, 2019